A New Class of Living Therapeutics with Great Potential to Treat Incurable Diseases
We are innovators and biotechnology manufacturer that use our cutting-edge technologies to lead the industry forward.
Our established technology platforms enable us to manufacture clinical-grade "off-the-shelf" Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC) from the unlimited source cord tissues that are traditionally regarded as medical waste. We embrace the advantages of hUC-MSC over MSC derived from other adult tissues including non-invasive procedure to the donor, robust proliferation, high ex vivo scalability and superior biological activities, etc. We also possess proprietary technologies to modify the hUC-MSC by chemical or genetic means to extend their therapeutic profile.
Our hUC-MSC based product candidates are aimed to be tested in FDA regulated clinical trials focusing on autoimmune diseases including Rheumatoid Arthritis (RA) and Crohn's disease (CD), liver disease, as well as advanced cancers.
Our Product Candidates
We have been developing two categories of the stem cell therapeutic product candidates: hUC-MSC for Autoimmune Diseases and engineered hUC-MSC for Malignant Diseases.